Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Bcl2 inhibitor

DRUG CLASS:

Bcl2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A1 - Approval venetoclax + rituximab Sensitive : A1	venetoclax + rituximab Sensitive: A1 - Approval venetoclax + rituximab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2